Anti-CD14 antibodies are widely used immunohistochemical reagents for identifying cells of the monocytic lineage in tissue sections. In hematopathology, detection of CD14 in formalin-fixed, paraffin-embedded (FFPE) specimens contributes to the immunophenotypic characterization of myeloid neoplasms and assists in the diagnostic evaluation of diseases with monocytic differentiation. When interpreted alongside morphologic findings and additional lineage markers, CD14 immunostaining can help characterize leukemic infiltrates and bone marrow abnormalities in routine diagnostic practice.

Biological Significance of CD14

• Monocytic lineage marker: CD14 is a cell-surface glycoprotein predominantly expressed on monocytes, macrophages, and related myeloid cells, making it an established marker of monocytic differentiation.
• Innate immune receptor component: CD14 functions as a co-receptor for lipopolysaccharide (LPS) and other pathogen-associated molecular patterns, participating in innate immune signaling pathways and inflammatory responses.
• Monocyte subset classification: Differential CD14 expression, together with CD16, is used to define human monocyte subsets, including classical CD14⁺CD16⁻ and intermediate CD14⁺CD16⁺ monocytes, reflecting functional heterogeneity within circulating monocytes.

These biological features make CD14 a useful immunophenotypic marker for identifying cells derived from the monocytic differentiation pathway in tissue sections.

Diagnostic Utility of CD14 in Hematopathology

• Identification of monocytic differentiation: CD14 immunostaining supports recognition of acute myeloid leukemias (AML) with monocytic or myelomonocytic differentiation.
• Characterization of monocytic neoplasms: CD14 is considered a relatively specific marker of monocytic lineage and is commonly used in combination with markers such as CD163 or CD68 to improve diagnostic accuracy.
• Bone marrow biopsy evaluation: Detection of CD14-positive cells in bone marrow cores can help demonstrate expanded monocytic populations, supporting the assessment of disorders such as chronic myelomonocytic leukemia (CMML).
• Complement to flow cytometry: In situations where flow cytometry is unavailable or inconclusive, CD14 immunohistochemistry on tissue sections may contribute to the immunophenotypic classification of myeloid leukemias when interpreted with other diagnostic markers.

Key Features of CE/IVD Anti-CD14 Antibodies for IHC

• Validated for immunohistochemistry on FFPE tissues, including bone marrow and hematologic specimens.
• Enable specific detection of monocytic lineage cells in tissue sections.
• Generally compatible with automated IHC staining platforms and standard antigen-retrieval protocols used in diagnostic laboratories.
• Provide reliable sensitivity and specificity for hematopathology workflows when used according to validated protocols.
• Suitable for multiplex diagnostic panels, commonly combined with markers such as CD68, CD163, myeloperoxidase (MPO), and CD34 for comprehensive immunophenotypic profiling of myeloid neoplasms.